Friedrich, S
Zeymer, U
Dechend, R
Hagedorn, I
Riemer, T
Zemmrich, C
Bramlage, P
Pittrow, D
Senges, J
Schmieder, R E http://orcid.org/0000-0003-2356-5883
Article History
Received: 16 May 2014
Revised: 4 August 2014
Accepted: 11 August 2014
First Online: 2 October 2014
Competing interests
: FS, UZ, RD, IT, CZ, PB, DP, JS and RES have received speaker’s fees and consulting honoraria from Novartis and other manufacturers of antihypertensive drugs. IH is a full-time employee of Novartis Pharma GmbH, Germany. TR reports no conflict of interest.